164 related articles for article (PubMed ID: 37752406)
1. Inhibition of Eukaryotic Initiating Factor eIF4E Overcomes Abemaciclib Resistance in Gastric Cancer.
Zha HL; Chen W; Shi W; Liao YY
Curr Med Sci; 2023 Oct; 43(5):927-934. PubMed ID: 37752406
[TBL] [Abstract][Full Text] [Related]
2. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.
Xu M; Tao Z; Wang S; Jiang Y; Qu M
Biochem Biophys Res Commun; 2019 May; 512(4):902-907. PubMed ID: 30929914
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2018 Sep; 503(4):2286-2292. PubMed ID: 29959920
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.
Cao J; Sun X; Zhang X; Chen D
Clin Transl Oncol; 2018 Jun; 20(6):761-767. PubMed ID: 29086249
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation.
Hu Z; Zhen L; Li Q; Han Q; Hua Q
Biochem Biophys Res Commun; 2019 Jun; 513(4):862-868. PubMed ID: 31000196
[TBL] [Abstract][Full Text] [Related]
6. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.
Pettersson F; Yau C; Dobocan MC; Culjkovic-Kraljacic B; Retrouvey H; Puckett R; Flores LM; Krop IE; Rousseau C; Cocolakis E; Borden KL; Benz CC; Miller WH
Clin Cancer Res; 2011 May; 17(9):2874-84. PubMed ID: 21415224
[TBL] [Abstract][Full Text] [Related]
7. Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer.
Jin J; Xiang W; Wu S; Wang M; Xiao M; Deng A
Biochem Biophys Res Commun; 2019 Mar; 510(4):580-586. PubMed ID: 30739792
[TBL] [Abstract][Full Text] [Related]
8. Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
Tan J; Ye J; Song M; Zhou M; Hu Y
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29112301
[TBL] [Abstract][Full Text] [Related]
9. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
10. Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation.
Ge S; Zhang Q; Chen Y; Tian Y; Yang R; Chen X; Li F; Zhang B
Toxicol Appl Pharmacol; 2021 Mar; 415():115450. PubMed ID: 33577917
[TBL] [Abstract][Full Text] [Related]
11. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
12. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of eIF4E signaling by ribavirin selectively targets lung cancer and angiogenesis.
Tan H; He L; Cheng Z
Biochem Biophys Res Commun; 2020 Aug; 529(3):519-525. PubMed ID: 32736668
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth.
Liang S; Guo R; Zhang Z; Liu D; Xu H; Xu Z; Wang X; Yang L
Oncol Rep; 2013 Jun; 29(6):2422-30. PubMed ID: 23588929
[TBL] [Abstract][Full Text] [Related]
15. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
Urtishak KA; Wang LS; Culjkovic-Kraljacic B; Davenport JW; Porazzi P; Vincent TL; Teachey DT; Tasian SK; Moore JS; Seif AE; Jin S; Barrett JS; Robinson BW; Chen IL; Harvey RC; Carroll MP; Carroll AJ; Heerema NA; Devidas M; Dreyer ZE; Hilden JM; Hunger SP; Willman CL; Borden KLB; Felix CA
Oncogene; 2019 Mar; 38(13):2241-2262. PubMed ID: 30478448
[TBL] [Abstract][Full Text] [Related]
16. AEG-1 induces gastric cancer metastasis by upregulation of eIF4E expression.
Wu S; Yang L; Wu D; Gao Z; Li P; Huang W; Wang X
J Cell Mol Med; 2017 Dec; 21(12):3481-3493. PubMed ID: 28661037
[TBL] [Abstract][Full Text] [Related]
17. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer.
Prabhu SA; Moussa O; Gonçalves C; LaPierre JH; Chou H; Huang F; Richard VR; Ferruzo PYM; Guettler EM; Soria-Bretones I; Kirby L; Gagnon N; Su J; Silvester J; Krisna SS; Rose AAN; Sheppard KE; Cescon DW; Mallette FA; Zahedi RP; Borchers CH; Del Rincon SV; Miller WH
Mol Cancer Ther; 2023 Feb; 22(2):192-204. PubMed ID: 36722142
[TBL] [Abstract][Full Text] [Related]
19. Migration and epithelial-to-mesenchymal transition of lung cancer can be targeted via translation initiation factors eIF4E and eIF4GI.
Attar-Schneider O; Drucker L; Gottfried M
Lab Invest; 2016 Sep; 96(9):1004-15. PubMed ID: 27501049
[TBL] [Abstract][Full Text] [Related]
20. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-β-Catenin Axis.
Shen X; Zhu Y; Xiao Z; Dai X; Liu D; Li L; Xiao B
Am J Med Sci; 2017 Aug; 354(2):182-189. PubMed ID: 28864377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
